HCA Healthcare (NYSE:HCA) Price Target Raised to $395.00 at Wells Fargo & Company

HCA Healthcare (NYSE:HCA) had its price objective hoisted by Wells Fargo & Company from $365.00 to $395.00 in a research note released on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

HCA has been the topic of several other research reports. Royal Bank of Canada lifted their target price on shares of HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Friday, August 23rd. Barclays lifted their target price on shares of HCA Healthcare from $376.00 to $396.00 and gave the company an “overweight” rating in a research report on Wednesday, July 24th. Truist Financial lifted their target price on shares of HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Morgan Stanley started coverage on shares of HCA Healthcare in a research report on Tuesday, September 3rd. They set an “equal weight” rating and a $427.00 price target on the stock. Finally, Leerink Partners upped their price objective on shares of HCA Healthcare from $367.00 to $396.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $367.15.

HCA Healthcare Trading Down 0.6 %

Shares of HCA Healthcare stock opened at $408.17 on Tuesday. The company has a debt-to-equity ratio of 27.11, a current ratio of 1.06 and a quick ratio of 0.94. The firm has a fifty day moving average price of $393.95 and a 200 day moving average price of $351.69. HCA Healthcare has a 1 year low of $215.96 and a 1 year high of $417.14. The stock has a market cap of $106.91 billion, a PE ratio of 20.35, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.97 by $0.53. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The firm had revenue of $17.49 billion during the quarter, compared to analysts’ expectations of $17.05 billion. During the same quarter last year, the company posted $4.29 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that HCA Healthcare will post 22.51 earnings per share for the current year.

Insider Transactions at HCA Healthcare

In related news, SVP Christopher F. Wyatt sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $360.20, for a total value of $1,440,800.00. Following the completion of the sale, the senior vice president now directly owns 40,449 shares in the company, valued at approximately $14,569,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of HCA Healthcare stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the transaction, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at $11,438,494.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Christopher F. Wyatt sold 4,000 shares of HCA Healthcare stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $360.20, for a total transaction of $1,440,800.00. Following the transaction, the senior vice president now directly owns 40,449 shares in the company, valued at approximately $14,569,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,202 shares of company stock worth $6,407,273 over the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. MFA Wealth Advisors LLC acquired a new position in shares of HCA Healthcare during the second quarter worth $27,000. Unique Wealth Strategies LLC acquired a new position in shares of HCA Healthcare during the second quarter worth $28,000. Bangor Savings Bank lifted its position in shares of HCA Healthcare by 112.5% during the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its position in shares of HCA Healthcare by 284.0% during the second quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after purchasing an additional 71 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. acquired a new stake in HCA Healthcare in the second quarter valued at $33,000. 62.73% of the stock is owned by institutional investors and hedge funds.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.